| Literature DB >> 18479788 |
Karim Dorgham1, Valérie Abadie, Mutsunori Iga, Oliver Hartley, Guy Gorochov, Behazine Combadière.
Abstract
Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA+1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA+CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18479788 DOI： 10.1016/j.vaccine.2008.04.003
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641